Wall St Engine(@wallstengine):AstraZeneca $AZN is launching a restructuring plan expected to generate $1.5B in annual savings, with up to $2B in one-time costs over the next three years. The company plans to reinvest those savings into its drug pipeline, which currently includes more than 180 projects. The move follows several late-stage clinical trial setbacks and growing competition from generic drugs. AstraZeneca is still targeting $80B in annual revenue and 20 new medicine launches by 2030. Meanwhile, Q3 revenue grew 7% to $16.21B, supported by double-digit growth in oncology, respiratory and immunology, and rare disease treatments.

2026.10.30 08:59

AstraZeneca $AZN is launching a restructuring plan expected to generate $1.5B in annual savings, with up to $2B in one-time costs over the next three years. The company plans to reinvest those savings into its drug pipeline, which currently includes more than 180 projects. The move follows several late-stage clinical trial setbacks and growing competition from generic drugs. AstraZeneca is still targeting $80B in annual revenue and 20 new medicine launches by 2030. Meanwhile, Q3 revenue grew 7% to $16.21B, supported by double-digit growth in oncology, respiratory and immunology, and rare disease treatments.